ES2229030T3 - Procedimiento de preparacion de 9-(2-(dietilfosfonometoxi)etil)-adenina. - Google Patents
Procedimiento de preparacion de 9-(2-(dietilfosfonometoxi)etil)-adenina.Info
- Publication number
- ES2229030T3 ES2229030T3 ES02016429T ES02016429T ES2229030T3 ES 2229030 T3 ES2229030 T3 ES 2229030T3 ES 02016429 T ES02016429 T ES 02016429T ES 02016429 T ES02016429 T ES 02016429T ES 2229030 T3 ES2229030 T3 ES 2229030T3
- Authority
- ES
- Spain
- Prior art keywords
- adenine
- approximately
- hydroxyethyl
- sodium
- sodium alkoxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 229960000643 adenine Drugs 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000011734 sodium Substances 0.000 claims abstract description 23
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 23
- VAQOTZQDXZDBJK-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethanol Chemical compound NC1=NC=NC2=C1N=CN2CCO VAQOTZQDXZDBJK-UHFFFAOYSA-N 0.000 claims abstract description 21
- -1 sodium alkoxide Chemical class 0.000 claims abstract description 21
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims abstract description 12
- SACBMARVYGBCAK-UHFFFAOYSA-N 9-[2-(diethoxyphosphorylmethoxy)ethyl]purin-6-amine Chemical compound N1=CN=C2N(CCOCP(=O)(OCC)OCC)C=NC2=C1N SACBMARVYGBCAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 150000004703 alkoxides Chemical class 0.000 claims description 2
- UXQPXWNAHMNXOR-UHFFFAOYSA-N diethoxyphosphorylmethyl phenylmethanesulfonate Chemical compound CCOP(=O)(OCC)COS(=O)(=O)CC1=CC=CC=C1 UXQPXWNAHMNXOR-UHFFFAOYSA-N 0.000 claims description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 abstract description 17
- 150000001875 compounds Chemical class 0.000 abstract description 5
- UOEFFQWLRUBDME-UHFFFAOYSA-N diethoxyphosphorylmethyl 4-methylbenzenesulfonate Chemical compound CCOP(=O)(OCC)COS(=O)(=O)C1=CC=C(C)C=C1 UOEFFQWLRUBDME-UHFFFAOYSA-N 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 abstract description 3
- IGIYRYJHUQPLTG-UHFFFAOYSA-N [2-(6-amino-7H-purin-2-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate Chemical compound C(C(C)(C)C)(=O)OCOP(=O)(OCOC(C(C)(C)C)=O)COCCC1=NC(=C2NC=NC2=N1)N IGIYRYJHUQPLTG-UHFFFAOYSA-N 0.000 abstract description 2
- SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 abstract description 2
- 150000002148 esters Chemical class 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- 150000002894 organic compounds Chemical class 0.000 description 6
- 238000013019 agitation Methods 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
- 229940011051 isopropyl acetate Drugs 0.000 description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- KVCGISUBCHHTDD-UHFFFAOYSA-M sodium;4-methylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1 KVCGISUBCHHTDD-UHFFFAOYSA-M 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Transplanting Machines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5377197P | 1997-07-25 | 1997-07-25 | |
| US90074597A | 1997-07-25 | 1997-07-25 | |
| US900745 | 1997-07-25 | ||
| US53771P | 1997-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2229030T3 true ES2229030T3 (es) | 2005-04-16 |
Family
ID=26732226
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02016429T Expired - Lifetime ES2229030T3 (es) | 1997-07-25 | 1998-07-23 | Procedimiento de preparacion de 9-(2-(dietilfosfonometoxi)etil)-adenina. |
| ES02016428T Expired - Lifetime ES2229029T3 (es) | 1997-07-25 | 1998-07-23 | Procedimiento de preparacion de adefovir dipivoxil. |
| ES98937988T Expired - Lifetime ES2187991T3 (es) | 1997-07-25 | 1998-07-23 | Composiciones de analogo de nucleotido. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02016428T Expired - Lifetime ES2229029T3 (es) | 1997-07-25 | 1998-07-23 | Procedimiento de preparacion de adefovir dipivoxil. |
| ES98937988T Expired - Lifetime ES2187991T3 (es) | 1997-07-25 | 1998-07-23 | Composiciones de analogo de nucleotido. |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0996430B1 (enExample) |
| JP (4) | JP3573713B2 (enExample) |
| KR (3) | KR100700089B1 (enExample) |
| CN (2) | CN1216062C (enExample) |
| AR (1) | AR016548A1 (enExample) |
| AT (3) | ATE228357T1 (enExample) |
| AU (1) | AU747163B2 (enExample) |
| BR (1) | BR9811552A (enExample) |
| CA (3) | CA2596320C (enExample) |
| CO (1) | CO4980869A1 (enExample) |
| DE (3) | DE69809749T2 (enExample) |
| DK (1) | DK0996430T3 (enExample) |
| ES (3) | ES2229030T3 (enExample) |
| HK (1) | HK1046357B (enExample) |
| ID (1) | ID28006A (enExample) |
| IL (1) | IL133461A (enExample) |
| IN (1) | IN190037B (enExample) |
| MY (1) | MY129451A (enExample) |
| NZ (1) | NZ501659A (enExample) |
| PT (3) | PT1256584E (enExample) |
| SI (2) | SI1256585T1 (enExample) |
| TR (3) | TR200200137T2 (enExample) |
| TW (1) | TW584635B (enExample) |
| WO (1) | WO1999004774A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9811552A (pt) * | 1997-07-25 | 2000-08-29 | Gilead Sciences Inc | Composições de análogos de nucleotìdeos |
| US6635278B1 (en) * | 1998-12-15 | 2003-10-21 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| TWI230618B (en) * | 1998-12-15 | 2005-04-11 | Gilead Sciences Inc | Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same |
| AP1466A (en) | 2000-07-21 | 2005-09-22 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same. |
| JP4476811B2 (ja) | 2002-05-13 | 2010-06-09 | メタバシス・セラピューティクス・インコーポレイテッド | Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ |
| JP4332496B2 (ja) | 2002-05-13 | 2009-09-16 | メタバシス・セラピューティクス・インコーポレイテッド | Ｐｍｅａおよびｐｍｐａ環生成合成 |
| CN100383149C (zh) * | 2002-11-12 | 2008-04-23 | 天津帝士力投资控股集团有限公司 | 一种新的晶状埃地双酯及其组合物 |
| US7417036B2 (en) | 2002-11-12 | 2008-08-26 | Tianjin Kinsly Pharmaceutical Co. Ltd. | Crystal form of adefovir dipivoxil and its preparation |
| CN1303089C (zh) * | 2002-11-19 | 2007-03-07 | 天津药物研究院 | 阿德福韦酯结晶形态及其制备方法 |
| CN100415756C (zh) * | 2003-10-14 | 2008-09-03 | 沈阳药科大学 | 草酸阿地福韦酯及其晶型和制备方法及用途 |
| CN100358907C (zh) * | 2004-03-31 | 2008-01-02 | 河北医科大学生物医学工程中心 | 一种非晶状阿德福韦酯的制备方法 |
| CN100374118C (zh) * | 2004-05-20 | 2008-03-12 | 江苏吴中中药研发有限公司 | 含有阿德福韦酯的滴丸剂及其制备方法 |
| MXPA06014013A (es) | 2004-06-08 | 2007-03-15 | Metabasis Therapeutics Inc | Sintesis mediada por acidos de lewis de esteres ciclicos. |
| JP5323476B2 (ja) * | 2005-06-13 | 2013-10-23 | 博瑞生物医葯技▲術▼（▲蘇▼州）有限公司 | ヌクレオチド類縁体プロドラッグおよびその製剤 |
| CN100395248C (zh) * | 2006-05-26 | 2008-06-18 | 华东理工大学 | 一种9-(二乙氧基磷酰基甲氧基乙基)-腺嘌啉的制备方法 |
| ITMI20071594A1 (it) * | 2007-08-02 | 2009-02-03 | Solmag Spa | Forma cristallina monoidrata di adefovir dipivoxil |
| CN101343290B (zh) * | 2008-05-24 | 2011-02-02 | 广东肇庆星湖生物科技股份有限公司 | 一种阿德福韦酯无水结晶物的制备方法、所得的阿德福韦酯无水结晶物及其应用 |
| WO2010005195A2 (ko) * | 2008-07-07 | 2010-01-14 | (주)아모레퍼시픽 | 아데포버 디피복실의 결정형 ｌ의 제조방법 |
| KR20100031045A (ko) | 2008-09-11 | 2010-03-19 | 씨제이제일제당 (주) | 아데포비어 디피복실의 정제방법 |
| JP2012502902A (ja) * | 2008-09-17 | 2012-02-02 | シージェイ チェルジェダン コーポレイション | アデホビルジピボキシルの安定化した固体分散体及びその製造方法 |
| KR20100032803A (ko) * | 2008-09-18 | 2010-03-26 | 씨제이제일제당 (주) | 아데포비어디피복실의 개선된 제조방법 |
| KR20100061401A (ko) * | 2008-11-28 | 2010-06-07 | (주)아모레퍼시픽 | 아데포버 디피복실의 결정형, 그 제조방법 및 그를 포함하는 약제학적 조성물 |
| RU2485121C1 (ru) * | 2009-03-26 | 2013-06-20 | Даевунг Фармасьютикал Ко., Лтд. | Новые кристаллические формы адефовира дипивоксила и способы его получения |
| KR20100113302A (ko) * | 2009-04-13 | 2010-10-21 | 한미홀딩스 주식회사 | 결정형 아데포비어 디피복실의 제조방법 및 이에 사용되는 아데포비어 디피복실 부탄올레이트 |
| KR101528754B1 (ko) * | 2009-04-14 | 2015-06-17 | 중앙대학교 산학협력단 | 신규한 복합결정형의 화합물, 그 제조방법 및 이를 포함하는 약제학적 조성물 |
| KR100971486B1 (ko) * | 2009-06-11 | 2010-07-21 | 주식회사 셀트리온화학연구소 | 아데포비어 다이피복실 말론산염 및 이를 포함하는 약제학적 조성물 |
| KR101089620B1 (ko) * | 2009-07-20 | 2011-12-06 | 경희대학교 산학협력단 | 무수결정형 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법 |
| WO2011016611A2 (ko) * | 2009-08-03 | 2011-02-10 | 제일약품주식회사 | 새로운 결정형을 갖는 아데포비어 디피복실, 이의 제조방법 및 이를 유효성분으로 함유하는 만성 ｂ형 간염의 예방 또는 치료용 조성물 |
| KR101129575B1 (ko) * | 2009-09-02 | 2012-03-28 | 경희대학교 산학협력단 | 반수화물 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법 |
| KR101048024B1 (ko) * | 2009-10-09 | 2011-07-13 | 주식회사 삼오제약 | 9-(2-포스포닐메톡시에틸)아데닌, 아데포비아 디피복실 및 무정형 아데포비아 디피복실의 제조방법 |
| EP2343056A1 (en) | 2009-12-30 | 2011-07-13 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Producing stable adefovir dipivoxil solid dispersions |
| WO2012032541A1 (en) * | 2010-09-06 | 2012-03-15 | Matrix Laboratories Ltd | "adefovir dipivoxil pseudopolymorph" |
| CN103221037A (zh) | 2010-11-12 | 2013-07-24 | 葛兰素惠尔康制造业私人有限公司 | 新药物组合物 |
| CN102250146A (zh) * | 2011-05-27 | 2011-11-23 | 扬州三友合成化工有限公司 | 抗乙肝药物阿德福韦的一种合成方法 |
| KR101357687B1 (ko) * | 2011-11-25 | 2014-02-05 | 숭실대학교산학협력단 | 고분자 첨가제를 이용한 아데포비어 디피복실 복합체의 결정입자 제어방법 및 이의 응용 |
| KR101258678B1 (ko) | 2012-02-29 | 2013-04-26 | 제일약품주식회사 | 새로운 결정형을 갖는 아데포비어 디피복실, 이의 제조방법 및 이를 유효성분으로 함유하는 만성 β형 간염의 예방 또는 치료용 조성물 |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| CN102816184B (zh) * | 2012-09-07 | 2015-11-18 | 山东大学 | (2-(2-氧基-4-硫代嘧啶)乙氧基)甲基膦酸酯类衍生物及其制备与应用 |
| CN103709198A (zh) * | 2012-09-28 | 2014-04-09 | 江苏天士力帝益药业有限公司 | 一种阿德福韦酯的结晶方法 |
| CN103333208B (zh) * | 2013-06-04 | 2016-05-11 | 广州晶莱医药科技有限公司 | 阿德福韦酯马来酸盐及其制备方法和组合物 |
| US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
| EP3164136A4 (en) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
| EP3372227A1 (en) | 2017-03-06 | 2018-09-12 | MH10 Spolka z ograniczona odpowiedzialnoscia | Tablet formulation of adefovir dipivoxil |
| CN111788196A (zh) | 2018-01-09 | 2020-10-16 | 配体药物公司 | 缩醛化合物及其治疗用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2118069T3 (es) * | 1990-09-14 | 1998-09-16 | Acad Of Science Czech Republic | Profarmacos de fosfonatos. |
| EP0632048B1 (en) * | 1993-06-29 | 2001-03-21 | Mitsubishi Chemical Corporation | Phosphonate-nucleotide ester derivatives |
| WO1998004569A1 (en) * | 1996-07-26 | 1998-02-05 | Gilead Sciences, Inc. | Nucleotide analogs |
| BR9811552A (pt) * | 1997-07-25 | 2000-08-29 | Gilead Sciences Inc | Composições de análogos de nucleotìdeos |
-
1998
- 1998-07-23 BR BR9811552-9A patent/BR9811552A/pt not_active Application Discontinuation
- 1998-07-23 AT AT98937988T patent/ATE228357T1/de active
- 1998-07-23 ES ES02016429T patent/ES2229030T3/es not_active Expired - Lifetime
- 1998-07-23 WO PCT/US1998/015304 patent/WO1999004774A2/en not_active Ceased
- 1998-07-23 AU AU86609/98A patent/AU747163B2/en not_active Expired
- 1998-07-23 CA CA002596320A patent/CA2596320C/en not_active Expired - Lifetime
- 1998-07-23 ES ES02016428T patent/ES2229029T3/es not_active Expired - Lifetime
- 1998-07-23 ID IDW20000153A patent/ID28006A/id unknown
- 1998-07-23 PT PT02016428T patent/PT1256584E/pt unknown
- 1998-07-23 DE DE69809749T patent/DE69809749T2/de not_active Expired - Lifetime
- 1998-07-23 TR TR2002/00137T patent/TR200200137T2/xx unknown
- 1998-07-23 DE DE69826734T patent/DE69826734T2/de not_active Expired - Lifetime
- 1998-07-23 DK DK98937988T patent/DK0996430T3/da active
- 1998-07-23 ES ES98937988T patent/ES2187991T3/es not_active Expired - Lifetime
- 1998-07-23 CA CA002298057A patent/CA2298057C/en not_active Expired - Lifetime
- 1998-07-23 TR TR2002/00117T patent/TR200200117T2/xx unknown
- 1998-07-23 PT PT98937988T patent/PT996430E/pt unknown
- 1998-07-23 KR KR1020057020625A patent/KR100700089B1/ko not_active Expired - Lifetime
- 1998-07-23 KR KR1019997012410A patent/KR100618663B1/ko not_active Expired - Lifetime
- 1998-07-23 NZ NZ501659A patent/NZ501659A/xx not_active IP Right Cessation
- 1998-07-23 AT AT02016429T patent/ATE277937T1/de active
- 1998-07-23 AT AT02016428T patent/ATE277936T1/de active
- 1998-07-23 IL IL13346198A patent/IL133461A/xx not_active IP Right Cessation
- 1998-07-23 SI SI9830716T patent/SI1256585T1/xx unknown
- 1998-07-23 EP EP98937988A patent/EP0996430B1/en not_active Expired - Lifetime
- 1998-07-23 DE DE69826735T patent/DE69826735T2/de not_active Expired - Lifetime
- 1998-07-23 PT PT02016429T patent/PT1256585E/pt unknown
- 1998-07-23 CN CN988037440A patent/CN1216062C/zh not_active Expired - Lifetime
- 1998-07-23 JP JP2000503833A patent/JP3573713B2/ja not_active Expired - Lifetime
- 1998-07-23 KR KR1020057020624A patent/KR100700087B1/ko not_active Expired - Lifetime
- 1998-07-23 SI SI9830712T patent/SI1256584T1/xx unknown
- 1998-07-23 CN CNB001370596A patent/CN1274700C/zh not_active Expired - Lifetime
- 1998-07-23 CA CA002596497A patent/CA2596497C/en not_active Expired - Lifetime
- 1998-07-23 TR TR2000/00224T patent/TR200000224T2/xx unknown
- 1998-07-24 CO CO98042226A patent/CO4980869A1/es unknown
- 1998-07-24 IN IN2176DE1998 patent/IN190037B/en unknown
- 1998-07-24 TW TW087112169A patent/TW584635B/zh not_active IP Right Cessation
- 1998-07-24 MY MYPI98003396A patent/MY129451A/en unknown
- 1998-07-27 AR ARP980103692A patent/AR016548A1/es active IP Right Grant
-
2002
- 2002-09-06 HK HK02106589.2A patent/HK1046357B/zh not_active IP Right Cessation
-
2003
- 2003-05-26 JP JP2003148228A patent/JP4452034B2/ja not_active Expired - Lifetime
-
2005
- 2005-05-18 JP JP2005145754A patent/JP2005306879A/ja not_active Withdrawn
-
2009
- 2009-07-01 JP JP2009157357A patent/JP2009263389A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2229030T3 (es) | Procedimiento de preparacion de 9-(2-(dietilfosfonometoxi)etil)-adenina. | |
| US5003097A (en) | Method for the sulfurization of phosphorous groups in compounds | |
| Tawfik et al. | 1, 8-Diazabicyclo [5.4. 0] undecene mediated transesterification of p-nitrophenyl phosphonates: a novel route to phosphono esters | |
| EP3390416B1 (en) | Phospholipidation of imidazoquinolines and oxoadenines | |
| ES2197491T3 (es) | Sintesis en fase de solucion de oligonucleotidos. | |
| AU2019202552B2 (en) | Chemical process for preparing pyrimidine derivatives and intermediates thereof | |
| US3134801A (en) | Process for the preparation of o,o-dialkyl-dithiophosphoryl-fatty acid compounds and pesticidal compositions containing the same | |
| EP0195277B1 (de) | Verfahren und Mittel zur Phosphorylierung | |
| EP0454427A1 (en) | Antiretroviral bases | |
| US20030099981A1 (en) | Process for the preparation of phosphorothioate triesters | |
| EP1256585B1 (en) | Process for preparing 9-(2-(diethylphosphonomethoxy)ethyl)-adenine | |
| JPH0531560B2 (enExample) | ||
| JPH11513681A (ja) | 重合可能なホスホジエステルの合成 | |
| Harger | Preparation and characterisation of N-(diphenylphosphinoyl) hydroxylamine, and conversion into O-sulphonyl derivatives that undergo Lossen-like rearrangement | |
| JPH085905B2 (ja) | ビス―（２，４―ジ―第三ブチルフェニル）ハロホスフィットの製造方法 | |
| JP2730928B2 (ja) | ハロリン化合物とフツ素とのハロゲン交換方法 | |
| Zamaratski et al. | Synthesis of phenazine-tethered arabino and xylofuranosyl oligonucleotide conjugates: The thermal stability and fluorescence properties of their duplexes (DNA-DNA & DNA-RNA) & triplexes | |
| EP0144386B1 (en) | Novel preparation of nucleoside phosphoramidite intermediates | |
| Sekine et al. | Chemical synthesis of oligonucleotides by use of phenylthio group | |
| Bollmark et al. | A new entry to nucleoside phosphorofluoridate and nucleoside phosphorofluoridothioate diesters | |
| US6284909B1 (en) | Preparations of thiophosphites and thiophosphonates | |
| Nagai et al. | Reinvestigation of deoxyribonucleoside phosphorothioites: synthesis and properties of deoxyribonudeoside-3′ dimethyl phosphites | |
| HK1051694B (en) | Process for preparing 9-(2-(diethylphosphonomethoxy)ethyl)-adenine | |
| US3187036A (en) | Process for the production of o, o-dimethyl dithiophosphoryl acetic acid alkyl amides | |
| JPS5949234B2 (ja) | Ｓ−アルキルホスホロジハロゲニドジチオエ−トの製造方法 |